RACHEL DAVENPORT-CAMPBELL: Open Payments
NPI 1710281399 · LONDON, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,742 in 88 payments from 18 companies in 2025. Trend: 2023 $1,353 · 2024 $1,614 · 2025 $1,742
Food & beverage: $1,654Education: $88
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 26 | $446 |
| AstraZeneca Pharmaceuticals LP | 11 | $218 |
| HARMONY BIOSCIENCES LLC | 8 | $198 |
| Amgen Inc. | 5 | $128 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $112 |
| GENZYME CORPORATION | 5 | $109 |
| Electromed, Inc. | 7 | $88 |
| Verona Pharma, Inc. | 4 | $88 |
| Grifols USA, LLC | 4 | $79 |
| Insmed, Inc. | 3 | $73 |
Products named: NUCALA, TEZSPIRE, TRELEGY ELLIPTA, DUPIXENT, WAKIX, FASENRA, SMARTVEST, Ohtuvayre.
Industry payments across KY — which companies pay providers there.
